104 related articles for article (PubMed ID: 31305121)
1. NKAP plays an oncogenic function partly through AKT signaling pathway in hepatocellular carcinoma.
Song T; Liu JY; Yang JJ
Neoplasma; 2019 Sep; 66(5):792-800. PubMed ID: 31305121
[TBL] [Abstract][Full Text] [Related]
2. NKAP functions as an oncogene in Ewing sarcoma cells partly through the AKT signaling pathway.
Li F; Wu JT; Wang PF; Qu LZ
Exp Ther Med; 2019 Oct; 18(4):3037-3045. PubMed ID: 31555387
[TBL] [Abstract][Full Text] [Related]
3. NKAP promotes renal cell carcinoma growth via AKT/mTOR signalling pathway.
Ma Q; Hou L; Gao X; Yan K
Cell Biochem Funct; 2020 Jul; 38(5):574-581. PubMed ID: 32032976
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of NF-κB activating protein promotes pancreatic cancer growth and metastasis through mTOR signaling pathway.
Xu X; Hou D; Wang Y; Zhang J; Hei Y; Wang B; Tian S; Zhang Y; Wang F
Mol Biol Rep; 2023 Sep; 50(9):7501-7513. PubMed ID: 37486443
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic role of NKAP in the growth and invasion of colon cancer cells.
Shu W; Liu G; Dai Y; Feng A; Chen Z; Han J; Li X
Oncol Rep; 2019 Nov; 42(5):2130-2138. PubMed ID: 31545474
[TBL] [Abstract][Full Text] [Related]
6. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
7. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
8. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
9. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
10. CCT4 suppression inhibits tumor growth in hepatocellular carcinoma by interacting with Cdc20.
Li F; Liu CS; Wu P; Ling AS; Pan Q; Li XN
Chin Med J (Engl); 2021 Nov; 134(22):2721-2729. PubMed ID: 34732665
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Rab5a promotes hepatocellular carcinoma cell proliferation and invasion via FAK signaling pathway.
Geng D; Zhao W; Feng Y; Liu J
Tumour Biol; 2016 Mar; 37(3):3341-7. PubMed ID: 26443539
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA‑9‑5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway.
Dong X; Wang F; Xue Y; Lin Z; Song W; Yang N; Li Q
Int J Mol Med; 2019 Mar; 43(3):1417-1429. PubMed ID: 30664155
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.
Cho SB; Park YL; Song YA; Kim KY; Lee GH; Cho DH; Myung DS; Park KJ; Lee WS; Chung IJ; Choi SK; Kim KK; Joo YE
Oncol Rep; 2011 Dec; 26(6):1581-6. PubMed ID: 21874262
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation.
Guo J; Cheng X; Tian Y; Li B; Zhang X; Gao X; An Y
Reprod Biol; 2021 Sep; 21(3):100534. PubMed ID: 34271243
[TBL] [Abstract][Full Text] [Related]
16. Eukaryotic elongation factor-1α 2 knockdown inhibits hepatocarcinogenesis by suppressing PI3K/Akt/NF-κB signaling.
Qiu FN; Huang Y; Chen DY; Li F; Wu YA; Wu WB; Huang XL
World J Gastroenterol; 2016 Apr; 22(16):4226-37. PubMed ID: 27122673
[TBL] [Abstract][Full Text] [Related]
17. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
18. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
19. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells].
Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734
[TBL] [Abstract][Full Text] [Related]
20. Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway.
Wu L; Zheng J; Chen P; Liu Q; Yuan Y
Biomed Pharmacother; 2017 Jun; 90():705-712. PubMed ID: 28419966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
